Sectors & IndustriesHealthcare

Best Healthcare Stocks to Buy Now (2026)

Top healthcare stocks in 2026 ranked by overall Due Diligence Score. See the best healthcare stocks to buy now, according to analyst forecasts for the healthcare sector.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best healthcare stocks to buy right now are:

Bioventus (NASDAQ:BVS) is the #1 top healthcare stock out of 1077 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Bioventus (NASDAQ:BVS) is: Value: A, Growth: A, Momentum: C, Sentiment: C, Safety: B, Financials: A, and AI: C.

Bioventus (NASDAQ:BVS) has a Due Diligence Score of 47, which is 20 points higher than the healthcare sector average of 27. It passed 15 out of 33 due diligence checks and has strong fundamentals. Bioventus has seen its stock lose -11.1% over the past year, overperforming other healthcare stocks by 23 percentage points.

Bioventus has an average 1 year price target of $15.00, an upside of 78.36% from Bioventus's current stock price of $8.41.

Bioventus stock has a consensus Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Bioventus, 0% have issued a Strong Buy rating, 100% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Indivior Pharmaceuticals (NASDAQ:INDV) is the #2 top healthcare stock out of 1077 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Indivior Pharmaceuticals (NASDAQ:INDV) is: Value: B, Growth: B, Momentum: C, Sentiment: A, Safety: B, Financials: B, and AI: C.

Indivior Pharmaceuticals (NASDAQ:INDV) has a Due Diligence Score of 40, which is 13 points higher than the healthcare sector average of 27. It passed 13 out of 33 due diligence checks and has average fundamentals. Indivior Pharmaceuticals has seen its stock return 226.29% over the past year, overperforming other healthcare stocks by 260 percentage points.

Indivior Pharmaceuticals has an average 1 year price target of $44.50, an upside of 37.9% from Indivior Pharmaceuticals's current stock price of $32.27.

Indivior Pharmaceuticals stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Indivior Pharmaceuticals, 50% have issued a Strong Buy rating, 50% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Amneal Pharmaceuticals (NASDAQ:AMRX) is the #3 top healthcare stock out of 1077 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Amneal Pharmaceuticals (NASDAQ:AMRX) is: Value: B, Growth: A, Momentum: B, Sentiment: B, Safety: C, Financials: C, and AI: C.

Amneal Pharmaceuticals (NASDAQ:AMRX) has a Due Diligence Score of 35, which is 8 points higher than the healthcare sector average of 27. It passed 11 out of 33 due diligence checks and has average fundamentals. Amneal Pharmaceuticals has seen its stock return 51.14% over the past year, overperforming other healthcare stocks by 85 percentage points.

Amneal Pharmaceuticals has an average 1 year price target of $14.75, an upside of 11.4% from Amneal Pharmaceuticals's current stock price of $13.24.

Amneal Pharmaceuticals stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Amneal Pharmaceuticals, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 69 healthcare stocks that have issued dividends in the past year, the 3 healthcare stocks with the highest dividend yields are:

Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 22.32%, which is 20 percentage points higher than the healthcare sector average of 2.16%.

Dominari Holdings's dividend payout ratio of 8.4% indicates that its high dividend yield is sustainable for the long-term.

Spok Holdings (NASDAQ:SPOK) has an annual dividend yield of 9.97%, which is 8 percentage points higher than the healthcare sector average of 2.16%. Spok Holdings's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Spok Holdings's dividend has shown consistent growth over the last 10 years.

Spok Holdings's dividend payout ratio of 162.3% indicates that its high dividend yield might not be sustainable for the long-term.

Oramed Pharmaceuticals (NASDAQ:ORMP) has an annual dividend yield of 7.61%, which is 5 percentage points higher than the healthcare sector average of 2.16%.

Oramed Pharmaceuticals's dividend payout ratio of 0% indicates that its high dividend yield might not be sustainable for the long-term.

Healthcare stocks were down -1.08% in the last day, and down -4.26% over the last week. Calidi Biotherapeutics was the among the top losers in the healthcare sector, dropping -53.12% yesterday.

Calidi Biotherapeutics shares are trading lower after the company announced the pricing of its $5.2 million offering of 10.5 million shares.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued healthcare stocks right now are:

Embecta (NASDAQ:EMBC) is the most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Embecta has a valuation score of 86, which is 68 points higher than the healthcare sector average of 18. It passed 6 out of 7 valuation due diligence checks.

Embecta's stock has dropped -29.58% in the past year. It has overperformed other stocks in the healthcare sector by 4 percentage points.

Ironwood Pharmaceuticals (NASDAQ:IRWD) is the second most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Ironwood Pharmaceuticals has a valuation score of 86, which is 68 points higher than the healthcare sector average of 18. It passed 6 out of 7 valuation due diligence checks.

Ironwood Pharmaceuticals's stock has gained 125.81% in the past year. It has overperformed other stocks in the healthcare sector by 160 percentage points.

Harmony Biosciences Holdings (NASDAQ:HRMY) is the third most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 71, which is 53 points higher than the healthcare sector average of 18. It passed 5 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has dropped -15.96% in the past year. It has overperformed other stocks in the healthcare sector by 18 percentage points.

57.42% of healthcare stocks rated by analysts are a strong buy right now. On average, analysts expect healthcare stocks to rise by 43.82% over the next year.

6.38% of healthcare stocks have a Zen Rating of A (Strong Buy), 12.15% of healthcare stocks are rated B (Buy), 49.58% are rated C (Hold), 24.31% are rated D (Sell), and 7.58% are rated F (Strong Sell).